ABSTRACT
Glass composition‐based correlations of volcanic ash (tephra) traditionally rely on extensive manual plotting. Many previous statistical methods for testing correlations are limited by using ...geochemical means, masking diagnostic variability. We suggest that machine learning classifiers can expedite correlation, quickly narrowing the list of likely candidates using well‐trained models. Eruptives from Alaska's Aleutian Arc‐Alaska Peninsula and Wrangell volcanic field were used as a test environment for 11 supervised classification algorithms, trained on nearly 2000 electron probe microanalysis measurements of glass major oxides, representing 10 volcanic sources. Artificial neural networks and random forests were consistently among the top‐performing learners (accuracy and kappa > 0.96). Their combination as an average ensemble effectively improves their performance. Using this combined model on tephras from Eklutna Lake, south‐central Alaska, showed that predictions match traditional methods and can speed correlation. Although classifiers are useful tools, they should aid expert analysis, not replace it. The Eklutna Lake tephras are mostly from Redoubt Volcano. Besides tephras from known Holocene‐active sources, Holocene tephra geochemically consistent with Pleistocene Emmons Lake Volcanic Center (Dawson tephra), but from a yet unknown source, is evident. These tephras are mostly anchored by a highly resolved varved chronology and represent new important regional stratigraphic markers.
To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients.
Double-blind, randomized, placebo-controlled study.
Patients were >or=18 years old, with body mass ...index of 27-43 kg m(-2), and 51% with metabolic syndrome (MS) randomized to placebo (N=417) or taranabant 2 mg (N=414), 4 mg (N=415) or 6 mg (N=1256) for 104 weeks.
Key efficacy measurements included body weight, waist circumference (WC), lipid and glycemic end points.
On the basis of risk/benefit assessments, the 6-mg dose was discontinued during year 1 (patients on 6 mg were down-dosed to 2 mg or placebo) and the 4-mg dose was discontinued during year 2 (patients on 4 mg were down-dosed to 2 mg). Changes from baseline in body weight at week 52 (all-patients-treated population, last observation carried forward analysis) were -2.6, -6.6 and -8.1 kg, respectively, for placebo and taranabant 2 and 4 mg (both doses P<0.001 vs placebo). For patients who completed year 1, changes from baseline in body weight at week 104 were -1.4, -6.4 and -7.6 kg for placebo and taranabant 2 and 4 mg, respectively (both doses P<0.001 vs placebo). The proportions of patients at weeks 52 and 104 who lost at least 5 and 10% of their baseline body weight were significantly higher and the proportions of patients who met criteria for MS were significantly lower for taranabant 2 and 4 mg vs placebo. The incidence of adverse experiences classified in the gastrointestinal, nervous, psychiatric, cutaneous and vascular organ systems were generally observed to be dose related with taranabant vs placebo.
Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences. On the basis of these and other data, an assessment was made that the overall safety and efficacy profile of taranabant did not support its further development for the treatment of obesity.
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The ...phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with the recombinant human hyaluronidase PH20 enzyme (rHuPH20) in patients with relapsed or refractory MM. Part 1 of the study, reported here, evaluated a mix-and-deliver (MD) formulation of daratumumab and rHuPH20 (DARA-MD) administered by subcutaneous infusion. Patients received subcutaneous daratumumab according to the approved IV monotherapy dosing schedule at 1200 mg (n = 8) or 1800 mg (n = 45). Primary end points were safety and pharmacokinetic (PK) variables. The most common treatment-emergent adverse events with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased appetite (37.5% each). Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7% each) were the most common treatment-emergent adverse events with DARA-MD 1800 mg. One patient in the 1200-mg dose group (12.5%) and 11 patients in the 1800-mg dose group (24.4%) experienced infusion-related reactions, which were generally grade 1/2 and typically occurred at the first infusion. The 1800 mg dose achieved similar or greater serum concentrations compared with the 16 mg/kg IV dose. Overall response rates of 25.0% and 42.2% were achieved with 1200-mg and 1800-mg DARA-MD, respectively. Subcutaneous administration of DARA-MD was well tolerated in patients with relapsed or refractory MM, with the 1800-mg dose exhibiting PK concentrations and responses consistent with IV daratumumab in a similar patient population. This study was registered at www.clinicaltrials.gov as #NCT02519452.
•Subcutaneously administered daratumumab had similar safety and PK profile, and lower infusion-related reactions, compared with the IV formulation.•The 1800-mg subcutaneous dose of daratumumab induced deep, durable responses in patients with heavily pretreated MM.
Display omitted
Most published epidemiology studies of long-term air pollution health effects have relied on central site monitoring to investigate regional-scale differences in exposure. Few cohort studies have had ...sufficient data to characterize localized variations in pollution, despite the fact that large gradients can exist over small spatial scales. Similarly, previous data have generally been limited to measurements of particle mass or several of the criteria gases. The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air) is an innovative investigation undertaken to link subclinical and clinical cardiovascular health effects with individual-level estimates of personal exposure to ambient-origin pollution. This project improves on prior work by implementing an extensive exposure assessment program to characterize long-term average concentrations of ambient-generated PM2.5, specific PM2.5 chemical components, and copollutants, with particular emphasis on capturing concentration gradients within cities. This paper describes exposure assessment in MESA Air, including questionnaires, community sampling, home monitoring, and personal sampling. Summary statistics describing the performance of the sampling methods are presented along with descriptive statistics of the air pollution concentrations by city.
On March 25 and 26, 2015, the National Heart, Lung, and Blood Institute sponsored a meeting on the State of the Science in Transfusion Medicine on the National Institutes of Health (NIH) campus in ...Bethesda, Maryland, which was attended by a diverse group of 330 registrants. The meeting's goal was to identify important research questions that could be answered in the next 5 to 10 years and which would have the potential to transform the clinical practice of transfusion medicine. These questions could be addressed by basic, translational, and/or clinical research studies and were focused on four areas: the three “classical” transfusion products (i.e., red blood cells, platelets, and plasma) and blood donor issues. Before the meeting, four working groups, one for each area, prepared five major questions for discussion along with a list of five to 10 additional questions for consideration. At the meeting itself, all of these questions, and others, were discussed in keynote lectures, small‐group breakout sessions, and large‐group sessions with open discourse involving all meeting attendees. In addition to the final lists of questions, provided herein, the meeting attendees identified multiple overarching, cross‐cutting themes that addressed issues common to all four areas; the latter are also provided. It is anticipated that addressing these scientific priorities, with careful attention to the overarching themes, will inform funding priorities developed by the NIH and provide a solid research platform for transforming the future practice of transfusion medicine.
Reduced-intensity conditioning (RIC) permits allogeneic hematopoietic progenitor cell transplantation in patients who would not be considered candidates for transplantation using a myeloablative ...preparative regimen because of age, comorbidities or prior therapy. In the setting of myeloablative transplantation, use of antithymocyte globulin (ATG) can reduce the risk of GVHD without negatively affecting transplant outcomes; however, limited data exist on the impact of ATG in the setting of RIC, particularly when there is HLA-mismatch. We performed a retrospective analysis of 85 patients who received unrelated donor transplants at our institution for hematologic malignancies following conditioning with fludarabine and melphalan (FluMel), with or without rabbit ATG (6 mg/kg). ATG was targeted to patients receiving HLA-mismatched grafts. With a median follow-up of 36 months, those receiving ATG and a mismatched graft had similar rates of acute and chronic GVHD, relapse, and similar OS compared with those receiving HLA-matched grafts without ATG. In a multivariate analysis, HLA-mismatched donor was not associated with a decrement in OS. We conclude that this intermediate dose of ATG is effective in preventing severe GVHD in the setting of HLA-mismatch, without undue compromise of the graft versus tumor effects on which RIC transplants depend.
The NASA moderate resolution imaging spectroradiometer (MODIS) instrument will provide a global and improved source of information for the study of land surfaces with a spatial resolution of up to ...250 m. Prior to the derivation of various biophysical parameters based on surface reflectances, the top of the atmosphere signals need to be radiometrically calibrated and corrected for atmospheric effects. The present paper describes in detail the state of the art techniques that will be used for atmospheric correction of MODIS bands 1 through 7, centered at 648, 858, 470, 555, 1240, 1640, and 2130 nm, respectively. Previous operational correction schemes have assumed a standard atmosphere with zero or constant aerosol loading and a uniform, Lambertian surface. The MODIS operational atmospheric correction algorithm, reported here, uses aerosol and water vapor information derived from the MODIS data, corrects for adjacency effects and takes into account the directional properties of the observed surface. This paper also describes the operational implementation of these techniques and its optimization. The techniques are applied to remote sensing data from the Landsat Thematic Mapper (TM), the NOAA advanced very high resolution radiometer (AVHRR), and the MODIS airborne simulator (MAS) and validated against ground‐based measurements from the Aerosol Robotic Network (AERONET).
PDF
